Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena
A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn't stopped contenders such as Roche's emicizumab.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.
Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores
BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
Here's a look at 100 experimental therapies in late-stage clinical trials.
Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China
Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials
Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel
Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
Opdivo fails in lung cancer trial; hedge fund sues Theranos; Takeda and Crescendo partner to develop humabody-based therapies
- In Merck video, woman says a cure is the greatest invention
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Thursday, April 20, 2017
- Five things for pharma marketers to know: Friday, April 21, 2017
- Five things for pharma marketers to know: Wednesday, April 19, 2017
- How pharma marketers are using behavioral science
- Veeva and QuintilesIMS tussle over customer reference data
- Genentech urges broader adoption of value-based payment models
- Some brands thought to shift online ad dollars, creating uncertainty for WebMD
- Study: Medical-marijuana laws lower prescription drug usage